At GENEUSBIOTECH we employ a carefully composed pipeline strategy considering every aspect of the interdisciplinary approaches necessary to lead our respective platform sequences to commercialization for the good of the animals and humans. Our approach is discussed in the attached Mc Kinsey article „A new portfolio model for biotech“ by J. Bleys et al. 2021
A few more normative models for pipeline strategies in life sciences - which were influential and the basics for our pipeline thesis - are described in the attached paper “Structuring the New Product Developing Pipeline” by M. Ding et al. 2002.